USPTO serial 86370005
BTG
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 24, 2016
- Examiner
- JACKSON, ELIZABETH FLEMING
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with BTG?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*
Plus Government fees of $1,700
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
London, GB
London EC4M 7RD, GB
London EC4M 7RD, GB
PROTHERICS MEDICINES DEVELOPMENT LIMITED
London, GB
Other trademarks owned by PROTHERICS MEDICINES DEVELOPMENT LIMITED
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jonathan A. Hyman
Jonathan A. Hyman Knobbe, Martens, Olson & Bear, LLP2040 Main Street, 14th FloorIrvine, CA 92614United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical, medicinal and veterinary preparations and substances, namely, [ vaccines, ] antitoxic sera, [ pharmaceutical preparations for the treatment of cancer, pharmaceutical preparations and substances for the treatment of thrombosis, embolisms, inflammation, and autoimmune disease, ] pharmaceutical preparations for the treatment of envenomation by snakes, veterinary preparations for the treatment of envenomation by snakes, [ and dietetic foods adapted for medical use, namely, food supplements containing vitamins, minerals, trace elements, oils and fats, either apart or in combinations thereof for use in the treatment of cardiovascular issues, vascular issues or cancer, liquid medical sealants, and liquid adhesives for use in surgical and clinical procedure ]; pharmaceutical and medicinal preparations and substances, namely, [ vaccines and vaccine adjuvants, proteins, peptides, ] sera containing polyclonal antibodies and fragments thereof and polyclonal antibodies and fragments derived therefrom all for use in treating snake envenomation, overdose of toxic substances [ , and sepsis; drug delivery agents, namely, preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals ]; pharmaceutical preparations and substances for use in the circulatory system; [ pharmaceutical preparations and substances for embolisation; pharmaceutical preparations and substances for embolisation of tumours and arteriovenous malformations (AVMs); pharmaceutical preparations and substances for use in the circulatory system for the treatment of tumours and AVMs; adjuvants for medicinal purposes, vaccine adjuvants and vaccine preparations containing adjuvant; ] chemical reagents for medical and veterinary purposes for the treatment of envenomation by snakes; chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes; chemico-pharmaceutical preparations for the treatment of envenomation by snakes; chemical preparations for medical and pharmaceutical purposes for the treatment of envenomation by snakes; medicines for the treatment of envenomation by snakes; pharmaceutical and veterinary preparations for the treatment of digoxin, digitalis and other cardio-active glycoside toxicity; pharmaceutical and veterinary preparations for the treatment of pre-eclampsia; chemical reagents for medical and veterinary therapeutic and diagnostic purposes; chemico-pharmaceutical preparations for use in the treatment of digoxin, digitalis and other cardio-active glycoside toxicity, and for use in the treatment of pre-eclampsia; chemical preparations for medical and pharmaceutical purposes and medicines for use in the treatment of digoxin, digitalis and other cardio-active glycoside toxicity and for use in the treatment of pre-eclampsia; [ transarterial chemoembolisation pharmaceutical preparations, vaccines and sera; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, therapeutic agents for delivery of radioactive materials to target sites within the body for the treatment of cancer; irradiated and radioactive microspheres used for in vivo therapeutic medical purposes, namely, beads in the nature of microscopic glass beads impregnated with radioactive pharmaceutical preparations for treatment of cancerous tumors; radiotherapy substances for medical purposes, namely, radioactive pharmaceutical preparations for medical purposes for the treatment of cancer; radiopharmaceuticals, namely, radiopharmaceuticals for the treatment of cancer and radiopharmaceutical preparations for use in nuclear medicine; therapeutic agents for delivery of radioactive material to target sites within the body; beads, including microscopic radioactive beads featuring pharmaceutical preparations for treatment of cancerous tumours; beads, including microscopic glass beads, impregnated with radioactive pharmaceutical preparations and consisting of radioactive material for treatment of cancerous tumours; radioactive glass beads impregnated with pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use with ultrasound waves to enhance drug delivery and medically activate drugs; pharmaceutical preparations in the form of foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams for use in producing foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams and for use in preparing foams, for sclerotherapy, phlebology, angiology and proctology, namely, for the treatment of oesophageal varices, hydroceles, in sterilisation treatment and for treatment of varicose veins, and arterio-venous malformations; ] pharmaceutical preparations containing methotrexate antidotes; pharmaceutical preparations containing 5-fluorouracil antidotes; pharmaceutical preparations for use in chemotherapy [ and for the treatment of autoimmune diseases ]; pharmaceutical preparations used for regulating toxicity levels of therapeutic agents; pharmaceutical preparations used for depleting concentrations of therapeutic agents | ACTIVE | — |
| 010 | Surgical, medical and veterinary apparatus and instruments, namely, medical syringes [ , surgical and medical apparatus for producing and administering pharmaceutical foams, surgical and medical apparatus for producing foams for treatment of varicose veins, arterio-venous malformations, oesophageal varices and hydroceles, devices for intravenous administration of pharmaceutical foam, and diagnostic devices for grading the severity of venous conditions, snake envenomation and toxic drugs overdose; surgical, medical and veterinary apparatus and instruments, namely, medical devices for use in pulmonary and thoracic surgery and procedures, lung air trapping reduction coils, lung volume reduction devices, surgical implants comprising artificial material, surgical implants comprising artificial materials for restoring, maintaining and improving patient breathing and artificial surgical implants for restoring, maintaining and improving lung function, and catheters for deploying these; surgical, medical and veterinary apparatus and instruments, namely, medical device, apparatus and instruments for treating cancer; drug delivery embolisation apparatus, instruments and systems ]; apparatus and instruments for use in the circulatory system, namely, [ catheters, ] injection syringes and sealed vials; [ medical apparatus and instruments for embolisation; surgical and medical apparatus and instruments, namely, catheters, injection syringes and sealed vial devices for dispensing microspheres during embolisation procedures in blood vessels and in the circulatory system; embolisation apparatus, instruments and systems comprising surgical and medical instruments for embolization, namely, embolic devices for use in treating cancer and tumors, embolic devices for treating arteriovenous malformations (AVMs) of the body, and embolic devices for use in treating tumors; drug delivery embolisation systems; ] drug delivery apparatus and instruments, namely, a drug delivery system comprised of injection syringes and sealed vials; [ injection syringes for use with catheters; ] apparatus and instruments for use in the circulatory system, namely, [ catheters, ] injection syringes and sealed vials for [ dispensing microspheres during embolisation procedures in blood vessels and in ] the circulatory system; [ medical apparatus and instruments for embolization, namely, medical devices in the nature of embolic microspheres for embolization; surgical and medical apparatus and instruments for embolisation, namely, embolisation apparatus, instruments and systems comprising microspheres and injection syringes for use in blood vessels and the circulatory system to carry out embolisation; radiotherapy apparatus; surgical and medical apparatus and instruments for delivery of radiopharmaceuticals and radioactive material to target sites within the body; beads, namely, microscopic radioactive glass beads administered surgically for treatment of cancerous tumours; radioactive beads, namely, radioactive glass beads administered for treatment of cancerous tumours; ] surgical and medical apparatus and instruments for use in the circulatory system [ ; medical devices in the nature of drug delivery systems which use ultrasound to enhance drug delivery and medically activate drugs; catheters for delivery of drugs and fluids sold together as a unit with controllers and power units for infusion catheters; ultrasonic drug delivery and drug activation apparatus sold together as a unit with controllers and power units therefor; needles for medical use, namely, cannula needles; medical tubing for sclerotherapy; medical tubing for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering sclerosing foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering foams for use in sclerotherapy, phlebology, angiology and proctology; syringes for producing and administering foams for use in sclerotherapy, phlebology, angiology and proctology; surgical and medical apparatus for administering and producing foams for use in sterilisation treatment; surgical and medical apparatus for use in treatment of varicose veins, arterio-venous malformations, oesophageal varices and hycroceles; syringes for use in treatment of varicose veins, arterio-venous malformations, oesophageal varices and hydroceles; devices for assessing the physical characteristics of such foams, namely, medical diagnostic apparatus for analyzing the efficacy of sclerotherapy foams for medical purposes; medical devices for intravenous administration of sclerosing foam for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; medical devices for monitoring the position and effect of sclerosing foam in the human body for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; medical diagnostic apparatus for diagnosing all the above medical conditions, namely, varicose veins, arterio-venous malformations, oesophageal varices, spider veins hydroceles, cancer, tumors, and circulatory system conditions and pulmonary and thoracic conditions; compression bandages; component parts and fittings for all of the aforesaid goods; irradiated or radioactive microspheres used for in vivo therapeutic medical purposes, namely, implantable radiation therapy devices consisting of radioactive beads in the nature of microscopic radioactive beads for treatment of cancerous tumours; implantable radiation therapy devices consisting of radioactive beads and a bioabsorbable carrier assembly, namely, beads in the nature of microscopic radioactive beads for treatment of cancerous tumours and beads in the nature of radioactive microscopic glass beads for treatment of cancerous tumours; radioactive glass beads, namely, implantable radiation therapy devices consisting of radioactive beads and a bioabsorbable carrier assembly and implantable radiation therapy devices consisting of radioactive beads; radioactive glass beads, namely, implantable radiation therapy devices consisting of radioactive glass beads administered for treatment of cancerous tumours ] | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BTG International Limited
- Other trademarks owned by BTG International Limited
- Other trademarks owned by BTG International Limited
- Other trademarks owned by PROTHERICS MEDICINES DEVELOPMENT LIMITED
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named BTG
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 29, 2026 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Jul 29, 2026 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Jul 29, 2026 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Jul 24, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| May 26, 2026 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| May 24, 2025 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Feb 14, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 14, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 14, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 14, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 14, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 13, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 13, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 13, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 11, 2023 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Apr 11, 2023 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Apr 7, 2023 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 16, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 16, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 16, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 16, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 16, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 28, 2022 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Apr 12, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 12, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 12, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Apr 12, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 12, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 12, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 30, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 30, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 30, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 30, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 30, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 24, 2021 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Apr 14, 2021 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Aug 29, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 29, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 29, 2020 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Aug 29, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 29, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 29, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 24, 2016 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 14, 2016 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Apr 3, 2016 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Feb 22, 2016 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Feb 22, 2016 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Sep 8, 2015 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 14, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 14, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 24, 2015 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 8, 2015 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jun 1, 2015 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 28, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 27, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 27, 2015 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 13, 2015 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Apr 13, 2015 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Apr 13, 2015 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Mar 21, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 20, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 20, 2015 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 21, 2014 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 21, 2014 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 21, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 14, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 30, 2014 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Aug 29, 2014 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 28, 2014 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Aug 21, 2014 | ALIE | ASSIGNED TO LIE | — |
| Aug 21, 2014 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Aug 21, 2014 | NWAP | NEW APPLICATION ENTERED | — |